| abstract |
A novel [1,2,4] triazolo [1,5-a] pyridine compound is disclosed having the formula represented by Formula I: The compounds may be prepared as pharmaceutical compositions, and include, but are not limited to, diseases involving, for example, cartilage degeneration, bone and / or joint degeneration, such as osteoarthritis, in mammals including humans; And / or diseases involving an inflammatory or immune response, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airway diseases (eg asthma, rhinitis), idiopathic arthritis, colitis, inflammatory bowel disease, endotoxin- Induced disease states (e.g., post-operative complications or e.g. chronic endotoxin conditions that cause chronic heart failure), diseases involving disorders of cartilage turnover (e.g., diseases involving catabolism of cartilage cells) ), Congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (eg organ graft rejection) and proliferative diseases, including the prevention and treatment of various diseases. |